Integrin-ligand interactions: Scratching the surface

Current Opinion in Hematology

Volumn 4, Issue 1, 1997, Pages 67-74

  Kanazashi, Shu Ichi ^a   Sharma, C Pal ^a   Arnaout, M Amin ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTEGRIN;

APOPTOSIS; CELL ADHESION; CELL SURFACE; CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; CYTOSKELETON; ENZYME ACTIVE SITE; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; LIGAND BINDING; MOLECULAR INTERACTION; PRIORITY JOURNAL; PROTEIN DOMAIN; REVIEW;

EID: 8044235625     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-199704010-00011     Document Type: Review

References (86)

1. Yamada KM, Miyamoto S: Integrin transmembrane signaling and cytoskeletal control. Curr Opin Cell Biol 1995, 7:681-689.
2. Gilmore AP, Burridge K: Molecular mechanisms for focal adhesion assembly through regulation of protein-protein interactions. Structure 1996, 4:647-651.
3. Parsons JT: Integrin-mediated signaling: regulation by protein tyrosine kinases and small GTP-binding proteins. Curr Opin Cell Biol 1996, 8:146-152.
4. Rieu P, Arnaout MA: The structural basis and regulation of β2 integrin interactions. In Adhesion Molecules and the Lung. Lung Biology in Health and Disease. Edited by Ward P, Fantone JC, Lenfant C. New York: Marcel Dekker; 1996, 89:1-42.
5. Detmers PA, Wright SD, Olsen E, Kimball B, Cohn ZA: Aggregation of complement receptors on human neutrophils in the absence of ligand. J Cell Biol 1987, 105:1137-1145.
6. Faull RJ, Kovach NL, Harlan JM, Ginsberg MH: Stimulation of integrin-mediated adhesion of T lymphocytes and monocytes: two mechanisms with divergent biological consequences. J Exp Med 1994, 179:1307-16.
7. Kucik DF, Dustin ML, Miller JM, Brown EJ: Adhesion-activating phorbol ester increases the mobility of leukocyte integrin LFA-1 in cultured lymphocytes. J Clin Invest 1996, 97:2139-2144.
8. Stewart MP, Cabanas C, Mogg N: T cell adhesion to intercellular adhesion molecule-1 (ICAM-1) is controlled by cell spreading and the activation of integrin LFA-1. J Immunol 1996, 156:1810-1817.
9. Wei Y, Lukashev M, Simon DI, Bodary SC, Rosenberg S, Doyle MV, Chapman HA: Regulation of integrin function by the urokinase receptor. Science 1996, 273:1551-1555. One of a series of recent papers showing important functional associations between integrins and other cell surface receptors. In this paper, the association of CD87 with integrin CR3 (CD11b/CD18) is shown to require prior activation of the integrin, and appears to be indirectly mediated through caveolin, a two-membrane spanner. Formation of a CD87-integrin complex leads to inhibition of integrin-mediated adhesion but facilitates CD87 adhesion to vitronectin.
10. Stockl J, Majdic O, Pickl WF, Rosenkranz A, Prager E, Gschwantler E, Knapp W: Granulocyte activation via a binding site near the C-terminal region of complement receptor type 3 alpha-chain (CD11b) potentially involved in intramembrane complex formation with glycosylphosphatidylinositol-anchored Fc gamma RIIIB (CD16) molecules. J Immunol 1995, 154:5452-5463.
11. Berditchevski F, Bazzoni G, Hemler ME: Specific association of CD63 with the VLA-3 and VLA-6 integrins. J Biol Chem 1995, 270:17784-17790.
12. Rubinstein E, Le Naour F, Billard M, Prenant M, Boucheix C: CD9 antigen is an accessory subunit of the VLA integrin complexes. Eur J Immunol 1994, 24:3005-3013.
13. Gao AG, Lindberg FP, Finn MB, Blystone SD, Brown EJ, Frazier WA: Integrin-associated protein is a receptor for the C-terminal domain of thrombospondin. J Biol Chem 1996, 271:21-24.
14. O'Toole TE, Mandelman D, Forsyth J, Shattil SJ, Plow EF, Ginsberg MH: Modulation of the affinity of integrin αIIbβ3 (GPIIb-IIIa) by the cytoplasmic domain of αIIβ. Science 1991, 254:845-847.
15. O'Toole TE, Katagiri Y, Faull RJ, Peter K, Tamura R, Quaranta V, Loftus JC, Shattil SJ, Ginsberg MH: Integrin cytoplasmic domains mediate inside-out signal transduction. J Cell Biol 1994, 124:1047-1059.
16. Peter K, O'Toole TE: Modulation of cell activation by changes in aLb2 (LFA-1, CD11a/CD18) cytoplasmic domain/cytoskeleton interaction. Exp Med 1995, 181:315-326. This study elucidates the role of a conserved triple threonine (TTT) motif in the cytoplasmic tail of CD18 on CD11a/CD18-mediated adhesion. A TTT to AAA substitution had no effect on receptor affinity yet reduced integrin-mediated spreading because of a decrease in the ability of the integrin to form focal adhesions and to organize the cytoskeleton into stress fibers. The authors suggest that the integrin β subunit cytoplasmic tails may be more important in modulating post-receptor binding events than in receptor affinity modulation.
17. Crowe DT, Chiu H, Fong S, Weissman IL: Regulation of the avidity of integrin α4β7 by the β7 cytoplasmic domain. J Biol Chem 1994, 269:14411-14418.
18. Hughes PE, Diaz-Gonzalez F, Leong L, Wu C, McDonald JA, Shattil SJ, Ginsberg MH: Breaking the integrin hinge. J Biol Chem 1996, 271:6571-6574.
19. Rabb H, Michishita M, Sharma CP, Brown D, Arnaout MA: Cytoplasmic tails of human complement receptor type 3 (CR3, CD11b/CD18) regulate ligand avidity and the internalization of occupied receptors. J Immunol 1993, 151:990-1002.
20. Chatila T, Geha RS, Arnaout MA: Constitutive and stimulus-induced phosphorylation of CD11/CD18 leukocyte adhesion molecules. J Cell Biol 1989, 109:3435-3444.
21. O'Toole TE: Regulation of integrin affinity states through an NPXY motif in the beta subunit cytoplasmic domain. J Biol Chem 1995, 270:8553-8558.
22. Filardo EJ, Brooks PC, Deming SL, Damsky C, Cheresh DA: Requirement of the NPXY motif in the integrin beta 3 subunit cytoplasmic tail for melanoma cell migration in vitro and in vivo. J Cell Biol 1995, 130:441-450.
23. LaFlamme SE, Akiyama SK, Yamada KM: Regulation of fibronectin receptor distribution. J Cell Biol 1992, 117:437-447.
24. Briesewitz R, Epstein MR, Marcantonio EE: Expression of native and truncated forms of the human integrin alpha 1 subunit. J Biol Chem 1993, 268:2989-2996.
25. Ylanne J, Chen Y, O'Toole TE, Loftus JC, Takada Y, Ginsberg MH: Distinct functions of integrins α and β subunit cytoplasmic domains in cell spreading and formation of focal adhesions. J Cell Biol 1993, 122:223-233.
26. Kassner PD, Alon R, Springer TA, Hemler ME: Specialized functional properties of the integrin αA cytoplasmic domain. Mol Biol Cell 1995, 6:661-674.
27. Shattil SJ, O'Toole T, Eigenthaler M, Thon V, Williams M, Babior BM, Ginsberg MH: Beta 3-endonexin, a novel polypeptide that interacts specifically with the cytoplasmic tail of the integrin beta 3 subunit J Cell Biol 1995, 131:807-816.
28. Hannigan GE, Leung-Hagesteijn C, Fitz-Gibbon L, Coppolino MG, Radeva G, Filmus J, Bell JC, Dedhar S: Regulation of cell adhesion and anchorage-dependent growth by a new beta 1 -integrin-linked protein kinase. Nature 1996, 379:91-96.
29. Kolanus W, Nagel W, Schiller B, Zeitlmann L, Godar S, Stockinger H, Seed B: aLb2 integrin/LFA-1 binding to ICAM-1 induced by cytohesin, a cytoplasmic regulatory molecule. Cell 1996, 86:233-242. Shattil et al. (J Cell Biol 1995, 131:807-816), Hannigan et al. (Nature 1996, 379:91-96), and Kolanus et al. (Cell 1996, 86:233-242) have identified novel proteins that interact with integrin βcytoplasmic tails using two-hybrid screens. Some of the identified proteins appear to be selective, while others can interact with more than one β subunit.
30. Main AL, Harvey TS, Baron M, Boyd J, Campbell ID: The three-dimensional structure of the tenth type-III module of fibronectin: an insight into RGD-mediated interactions. Cell 1992, 71:671-678.
31. Leahy DJ, Aukhil I, Erickson HP: A crystal structure of a four-domain segment of human fibronectin encompassing the RGD loop and synergy region. Cell 1996, 84:155-164. This paper reports the three-dimensional structure of a fragment of fibronectin containing type III repeats 7 to 10, the latter containing the RGD motif. The structure reveals the important interdomain relationships between the RGD loop in domain 10 and the "synergyregion of domain 9 (which has also been implicated in integrin binding). The structure reveals that both regions lie on the same face of the modular FN7-10 structure and are thus easily accessible for binding to a single integrin.
32. Leahy DJ, Hendrickson WA, Aukhil I, Erickson HP: Structure of a fibronectin type III domain from tenascin phased by MAD analysis of the selenomethionyl protein. Science 1992, 258:987-991.
33. Cooker RM, Carter BG, Murray-Ross P, Hartshorn MJ, Herzyk P, Hubbard RE: The solution structure echistatin: evidence for disulphide bond rearrangement in homologous snake toxins. Protein Eng 1992, 5:473-477.
34. Logand D, Abu-Ghazaleh R, Blakemore W, Curry S, Jackson T, King A, Lea S, Lewis R, Newman J, Parry N, Rowlands D, Stuart D, Fry E: Structure of a major immunogenic site on foot-and-mouth disease virus. Nature 1993, 362:566-568.
35. Jones EL, Harlos K, Bottomley MJ, Robinson RC, Driscoll PC, Edwards RM, Clements JM, Dudgeon TJ, Stuart DI: Crystal structure of an integrin-binding fragment of vascular cell adhesion molecule-1 at 1.8 A resolution. Nature 1995, 373:539-544. This paper reveals the first structure of an integrin ligand that is a member of the immunoglobulin family and identifies a second integrin binding motif that mediates integrin binding to ligands containing the immunoglobulin fold.
36. Overduin M, Harvey TS, Bagby S, Tong KI, Yau P, Takeichi M, Ikura M: Solution structure of the epithelial cadherin domain responsible for selective cell adhesion. Science 1995, 267:386-389.
37. Nagar B, Overduin M, Ikura M, Rini JM: Structural basis of calcium-induced E-cadherin rigidification and dimerization. Nature 1996, 380:360-364. This paper and that by Overduin et al. (Science 1995, 267:386-389) report the solution and crystal structures of E-cadherin, and suggest regions in the structure that may be involved in binding to integrins.
38. Osborn I, Vassallo C, Browning BG, Tizard R, Haskard DO, Benjamin CD, Dougas I, Kirchhausen T: Arrangement of domains, and amino acid residues required for binding of vascular cell adhesion molecule-1 to Its counter receptor VLA-4 (4β1). J Cell Biol 1994, 124:601-608.
39. Holness CL, Bates PA, Little AJ, Buckley CD, McDowall A, Bossy D, Hogg N, Simmons DL: Analysis of the binding site on intercellular adhesion molecule 3 for the leukocyte integrin lymphocyte function-associated antigen 1. J Biol Chem 1995, 270:877-884.
40. Sadhu C, Lipsky B, Erickson HP, Hayflick J, Dick KO, Gallatin WM, Staunton DE: LFA-1 binding site in ICAM-3 contains a conserved motif and non-contiguous amino acids. Cell Adhes Commun 1994, 2:429-440.
41. Beer JH, Springer KT, Coller BS: Immobilized Arg-Gly-Asp (RGD) peptides of varying lengths as structural probes of the platelet glycoprotein IIb/IIIa receptor. Blood 1992, 79:117-128.
42. Ueda T, Rieu P, Brayer J, Arnaout MA: Identification of the complement iC3b binding site In the β2 integrin CR3 (CD11b/CD18). Proc Natl Acad Sci U S A 1994, 91:10680-10684.
43. Huang C, Springer TA: A binding interface on the I domain of lymphocyte function-associated antigen-1 (LFA-1) required for specific interaction with intercellular adhesion molecule 1 (ICAM-1). J Biol Chem 1995, 270:19008-19016. This paper and that by Rieu et al. (J Biol Chem 1996, 271:15858-15861) reveal that the region surrounding MIDAS is involved in integrin binding to ligands.
44. Xie J, Li R, Kotovuori P, Vermot-Desroches C, Wijdenes J, Arnaout MA, Nortamo P, Gahmberg CG: Intercellular adhesion molecule-2 (CD102) binds to the leukocyte integrin CD11b/CD18 through the A domain. J Immunol 1995, 155:3619-3628.
45. Landis RC, McDowall A, Holness CL, Littler AJ, Simmons DL, Hogg N: Involvement of the "I" domain of LFA-1 in selective binding to ligands ICAM-1 and ICAM-3. J Cell Biol 1994, 126:529-537.
46. Randi AM, Hogg N: I Domain of β2 integrin lymphocyte-associated-antigen 1 contains a binding site for ligand intercellular adhesion molecule-1. J Biol Chem 1994, 269:12395-12398.
47. Tuckwell D, Calderwood DA, Green LJ, Humphries MJ: Integrin a2 I-domain is a binding site for collagens. J Cell Sci 1995, 108:1629-1637.
48. Zhou L, Lee DH, Plescia J, Lau CY, Altieri DC: Differential ligand binding specificities of recombinant CD11b/CD18 integrin I-domain. J Biol Chem 1994, 269:17075-17079.
49. Kern A, Briesewitz R, Bank I, Marcantonio EE: The role of the I domain in ligand binding of the human integrin alpha 1 beta 1. J Biol Chem 1994, 269:22811-22816.
50. Rieu P, Ueda T, Haruta I, Sharma CP, Arnaout MA: The A-domain of β2 integrin CR3 (CD11b/CD18) is a receptor for the hookworm-derived neutrophil adhesion inhibitor NIF. J Cell Biol 1994, 127:2081-2091.
51. King SL, Cunningham JA, Finberg RW, Bergelson JM: Echovirus 1 interaction with the isolated VLA-2 I domain. J Virol 1995, 69:3237-3239.
52. D'Souza SE, Ginsberg MH, Burke TA, Lam SC-T, Plow EE: Localization of an Arg-Gly-Asp recognition site within an integrin adhesion receptor. Science 1988, 242:91-93.
53. Smith JW, Cheresh DA: The Arg-Gly-Asp binding domain of the vitronectin receptor. J Biol Chem 1988, 263:18726-18731.
54. D'Souza SF, Haas TA, Piotrowicz RS, Byers WV, McGrath DE, Soule HR, Cierniewski C, Plow EF, Smith JW: Ligand and cation binding are dual functions of a discrete segment of the integrin beta 3 subunit: cation displacement is involved in ligand binding. Cell 1994, 73:659-67.
55. 3 (GPIIb-IIIa) receptor function. J Biol Chem 1994, 269:20913-20919.
56. Takada Y, Ylanne J, Mandelman D, Puzon W, Ginsberg MH: A point mutation of integrin β1 subunit blocks binding of α5β1 to fibronectin and invasin but not recruitment to adhesion plaques. J Cell Biol 1992, 119:913-921.
57. Charo IF, Nannizzi L, Phillips DR, Hsu MA, Scarborough RM: Inhibition of fibrinogen binding to GP IIb-IIIa by a GP IIIa peptide. J Biol Chem 1991, 266:1415-1421.
58. Mould AP, Akiyama SK, Humphries MJ: Regulation of integrin alpha 5 beta 1-fibronectin interactions by divalent cations. Evidence for distinct classes of binding sites for Mn2+, Mg2+, and Ca2+. J Biol Chem 1995, 270:26270-26277.
59. Lanza F, Stierle A, Fournier D, Morales M, Andre G, Nurden AT, Cazenave JP: A new variant of Glanzmann's thrombasthenia (Strasbourg I). Platelets with functionally defective glycoprotein IIb-IIIa complexes and a glycoprotein IIIa 214Arg→214Trp mutation. J Clin Invest 1992, 89:1995-2004.
60. Steiner B, Trzeciak A, Pfenninger G, Kouns WC: Peptides derived from a sequence within b3 integrin bind to platelet aIIbb3 (GPIIb-IIIa) and inhibit ligand binding. J Biol Chem 1993, 268:6870-6873.
61. Bajt ML, Ginsberg MH, Frelinger AL, Berndt MC, Loftus JC: A spontaneous mutation of integrin alpha IIb beta 3 (platelet glycoprotein (IIb-IIIa) helps define a ligand binding site. J Biol Chem 1992, 267:3789-3794.
62. Arnaout MA, Michishita M: Genetic abnormalities in leukocyte adhesion molecule deficiency. In Concepts in Immunodeficiency Diseases. Edited by Gupta S, Griscelli C. New York: Wiley & Sons; 1993:191-202.
63. Irie A, Kamata T, Puzon-McLaughlin W, Takada Y: Critical amino acid residues for ligand binding are clustered in a predicted b-turn of the third N-terminal repeat in the integrin a4 and a5 subunits. EMBO J 1995, 14:5550-5556.
64. D'Souza SE, Ginsberg MH, Matsueda GR, Plow EF: A discrete sequence in a platelet integrin is involved in ligand recognition. Nature 1991, 350:66-68.
65. Stanley P, Bates PA, Harvey J, Bennett RI, Hogg N: Integrin LFA-1 a subunit contains an ICAM-1 binding site in domains V and VI. EMBO J 1994, 13:1790-1798.
66. Lee J-O, Rieu P, Arnaout MA, Liddington R: Crystal structure of the A-domain from the α subunit of β2 integrin complement receptor type 3 (CR3, CD11b/CD18). Cell 1995, 80:631-638.
67. Lee J-O, Anne Bankston L, Arnaout MA, Liddington RC: Two conformations of the integrin A-domain (I-domain): a pathway for activation? Structure 1995, 3:1333-1340.
68. Qu A, Leahy DJ: Crystal structure of the I-domain from the CD11a/CD18 (LFA-1, αLβ2) integrin. Proc Natl Acad Sci U S A 1995, 92:10277-10281.
69. Qu A, Leahy DJ: The role of the divalent cation in the structure of the I domain from the CD11a/CD18 integrin. Structure 1996, 4:931-942. Papers by Lee et al. (Cell 1995, 80:631-638 and Structure 1995, 3:1333-1340) and Qu and Leahy (Proc Natl Acad Sci USA 1995, 92:10277-10281 and Structure 1996, 4:931-942) reveal the structure of metal-bound and free forms of the A-domain. These data suggest that the structure exists in different conformations that also affect the topology and electrostatic potential of the region surrounding MIDAS, and therefore the ability of the respective integrin to bind ligands.
70. Puzon-McLaughlin W, Takada Y: Critical residues for ligand binding in an I domain-like structure of the integrin β1 subunit J Biol Chem 1996, 271:20438-20443.
71. Zhang L, Plow EF: Overlapping, but not identical sites are involved in the recognition of C3bi, neutrophil inhibitory factor, and adhesive ligands by the aMb2 integrin. J Biol Chem 1996, 271:18211-18216.
72. Rieu P, Sugimori T, Griffith DL, Arnaout MA: Solvent accessible residues on the MIDAS face of integrin CR3 mediate its binding to the neutrophil adhesion/inhibitor NIF. J Biol Chem 1996, 271:15858-15861.
73. van Kooyk Y, Binnerts ME, Edwards CP, Champe M, Berman PW, Figdor CG, Bodary SC: Critical amino acids in the lymphocyte function-associated antigen-1 I domain mediate intercellular adhesion molecule 3 binding and immune function. J Exp Med 1996, 183:1247-1252.
74. Loftus JC, Halloran CE, Ginsberg MH, Feigen LP, Zablocki JA, Smith JW: The amino-terminal one-third of alpha IIb defines the ligand recognition specificity of integrin alpha lib beta 3. J Biol Chem 1996, 271:2033-2039. This paper reveals that the 334-amino-acid N-terminal region of the integrin α subunit is important for ligand binding specificity at least in integrins lacking the a A-domain.
75. Michishita M, Videm V, Arnaout MA: A novel divalent cation-binding site in the A domain of the β2 integrin CR3 (CD11b/CD18) is essential for ligand binding. Cell 1993, 72:857-867.
76. D'Souza SE, Haas TA, Piotrotrowicz RS, Byers- Ward V, McGrath DE, Soule HR, Cierniewski C, Plow EF, Smith JW: Ligand and cation binding are dual functions of a discrete segment of the integrin subunit: citation displacement is involved in ligand binding. Cell 1994, 79:659-667.
77. Arnaout MA: Structure and regulation of cell adhesion molecules. In Samter's Immunologic Diseases. Edited by Frank MM, Austen KF, Claman HN, Unanue ER. Boston: Little, Brown A Co.; 1995, 161-182.
78. Kelly T, Molony L, Burridge K: Purification of two smooth muscle glycoproteins related to integrin. J Biol Chem 1987, 262:17189-99.
79. Nermut MV, Green NM, Eason P, Yamada SS, Yamada KM: Electron microscopy and structural model of human fibronectin receptor. EMBO J 1988, 7:4093-4099.
80. Kieffer N, Phillips DR: Platelet membrane glycoproteins: functions in cellular interactions. Annu Rev Cell Biol 1990, 6:329-357.
81. Viney JL, Jones S, Chui HH, Lagrimas B, Renz ME, Presta LG, Jackson D, Hillan KJ, Lew S, Fong S: Mucosal addressin cell adhesion molecules-1: a structural and functional analysis demarcates the integrin binding motif. J Immunol 1996, 157:2488-2497.
82. Li R, Xie J, Kantor C, Koistinen V, Altieri DC, Nortamo P, Gahmberg CG: A peptide derived from the intercellular adhesion molecule-2 regulates the avidity of the leukocyte integrins CD11b/CD18 and CD11c/CD18. J Cell Biol 1995, 129:1143-1153.
83. Jang Y, Lincoff AM, Plow EF, Topol EJ: Cell adhesion molecules In coronary artery disease. J Am Coll Cardiol 1994, 24:1591-1601.
84. Staatz WD, Fok KF, Zutter MM, Adams SP, Rodriguez BA, Santoro SA: Identification of a tetrapeptide recognition sequence for the a2b1 Integrin in collagne. J Biol Chem 1991, 266:7363-7367.
85. Staunton DE, Dustin ML, Erickson HP, Springer TA: The arrangement of the Immunoglobulin-like domains of ICAM-1 and the binding sites for LFA-1 and rhinovirus. Cell 1990, 61:243-254.
86. Ruoslahti E, Noble NA, Kagami S, Broder WA: Integrins. Kidney Int 1994 45:S17-S22.